Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

NCT05318105 · View on ClinicalTrials.gov ↗

Study Summary

The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.

Interventions

  • DEVICE Aquadex Smartflow® System
  • DRUG IV Loop Diuretics

Study Locations (17)

California

  • MemorialCare, Long Beach Medical Center — Long Beach
  • Sharp Memorial Hospital, San Diego Cardiac Center — San Diego
  • University of California San Francisco — San Francisco

New York

  • Mount Sinai Morningside — New York
  • The Mount Sinai Hospital — New York
  • Northwell Health — New York

Florida

  • BayCare Medical Group, Morton Plant — Clearwater
  • St. Joseph's Hospital — Tampa

Ohio

  • The Christ Hospital — Cincinnati
  • The Ohio State University — Columbus

Arizona

  • Banner Health — Tucson

Kentucky

  • University of Kentucky — Lexington

Michigan

  • Henry Ford Health — Detroit

Pennsylvania

  • Abington Jefferson Health — Abington

Trial Details

FieldValue
Enrollment Target 372 participants
Start Date 2022-06-28
Est. Completion 2026-12-31
Phase NA

Sponsor

Nuwellis

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05318105

The ClinicalTrials.gov registry entry for NCT05318105 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuwellis, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions — of which Aquadex Smartflow® System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05318105 reports 17 study locations spanning 11 distinct geographic areas — top geographies include California, New York, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05318105 about?

NCT05318105 is a clinical study titled "Ultrafiltration Versus IV Diuretics in Worsening Heart Failure". The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.

What is the current status of trial NCT05318105?

This trial is currently recruiting. It is a NA study. The enrollment target is 372 participants. The study started on 2022-06-28. Estimated completion is 2026-12-31.

What conditions does trial NCT05318105 study?

This clinical trial studies the following conditions: Heart Failure, Fluid Overload, Heart Failure (for Example, Fluid Overload). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05318105?

The interventions under investigation include: Aquadex Smartflow® System (DEVICE), IV Loop Diuretics (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05318105?

This trial is sponsored by Nuwellis, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05318105 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial